NCT05445570

Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,002 (actual)
• Sponsor: Venn Biosciences Corporation · Industry
• Sex: All
• Age: 45 Years – 85 Years
• Healthy volunteers: —

Summary

The NICE study is a prospective, multi-site study to train and validate a blood-based, glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and associated relevant clinical information from average-risk participants who undergo routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indications

Detailed description

InterVenn is using its glycoprotein profiling technology platform that couples high-resolution liquid chromatography (LC)-mass spectrometry (MS) with an artificial intelligence (AI), neural network (NN)-based high-throughput data processing software to identify patterns uniquely associated with colon adenoma and colon adenocarcinoma in order to detect (pre)cancerous events early. The purpose of this prospective multi-center observational study is to train and validate a blood-based, glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and associated relevant clinical information from average-risk participants who undergo routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indications.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Non-Interventional	This is an observational, non interventional study

Timeline

• Start date: 2022-05-13
• Primary completion: 2024-03-19
• Completion: 2024-03-19
• First posted: 2022-07-06
• Last updated: 2024-04-23

Locations

12 sites across 1 country: United States